A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, diffuse large B-cell lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1 / Phase 2	2025-05-01		NCT05908409

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
IDP Discovery Pharma S.L.	2

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hospital Clínico Universitario Virgen de la Arrixaca	Murcia	Spain	15
Hospital de Clinico Universitario de Valencia	Valencia	Spain	1
Hospital Durán i Reynals - ICO L´Hospitalet	Barcelona	Spain	1
Hospital Universitari Vall d'Hebron	Barcelona	Spain	200
Hospital Universitario 12 de Octubre	Madrid	Spain	359
Hospital Universitario de Salamanca	Salamanca	Spain	9
Hospital Universitario La Paz	Madrid	Spain	75
Hospital Universitario Marques de Valdecilla	Santander	Spain	38
Hospital Universitario Miguel Servet	Zaragoza	Spain	27
Hospital Universitario Puerta de Hierro	Madrid	Spain	9
Hospital Universitario Virgen del Rocio	Seville	Spain	42